Primex Obtains Article 13 Health Claim for Chitosan

Iceland-based Primex has obtained approval from the European Food Safety Authority (EFSA) for an Article 13 health claim relating to its chitosan ingredient and maintenance of normal blood LDL-cholesterol. Based on submitted data, a scientific panel concluded that a cause and effect relationship has been established between the consumption of chitosan and maintenance of normal blood LDL-cholesterol concentrations. The panel considered that in order to obtain the claimed effect, 3 grams of chitosan should be consumed daily. The target population is adults.